Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01191307
Other study ID # 09-006C
Secondary ID
Status Terminated
Phase N/A
First received August 26, 2010
Last updated October 24, 2016
Start date March 2009
Est. completion date December 2014

Study information

Verified date October 2016
Source Food and Drug Administration (FDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The ASK CHILDREN study is intended to aid in future development of various neurologic devices (i.e. neuroprostheses). The ASK CHILDREN study seeks to use study information obtained to identify more efficient strategies in the evaluation and review of neuroprostheses regulated by the Agency.


Description:

The ASK CHILDREN study is intended to aid in future development of various neurologic devices (i.e. neuroprostheses). The ASK CHILDREN study seeks to use study information obtained to identify more efficient strategies in the evaluation and review of neuroprostheses regulated by the Agency. Specific aims of the clinical study include: (1) Collecting qualitative and quantitative self-report clinical data (through interviews) from children undergoing treatment related to human factors, safety, usability, and adverse events in patients ages 7 to 15 years old implanted with a neuroprosthesis targeting the brain or spinal cord (at two 6 month intervals); and (2) Establish a science-based framework of recommendations based upon the data collected in the ASK CHILDREN Study to help develop more efficient strategies in evaluating pediatric neuroprostheses regulated by the Agency.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 7 Years to 15 Years
Eligibility Primary Dystonia Inclusion Criteria

- Between ages 7 and 15 years of age;

- Implanted Medtronic Activa® Dystonia Therapy (approved or cleared by FDA for pediatric use).

- Neurologic device implanted within the past 12 months;

- Signed assent form document from the child

- Signed permission form from the parent/guardian); and

Exclusion Criteria

- Participation in another clinical investigation that could be jeopardized by participation in the current study;

- Children with severe cognitive impairments (such as children with head injuries resulting in severe cognitive impairment) may be excluded because they may not be capable of self-reporting procedures.

- Unable to comply with terms of the study

Epilepsy Inclusion Criteria

- Between ages 12 and 15 years of age;

- Neurologic device implantation or surgical (in-hospital) adjustment within the past 12 months;

- NeuroCybernetic Prosthesis (NCP®) System (approved or cleared by FDA for pediatric use; the NCP® System is approved for children in ages 12 years and older).

- Signed assent form document from the child; and

- Signed permission form from the parent/guardian).

Epilepsy Exclusion Criteria

- Participation in another clinical investigation that could be jeopardized by participation in the current study; and

- Children with severe cognitive impairments (such as children with head injuries resulting in severe cognitive impairment) may be excluded because they may not be capable of self-reporting procedures.6

- Unable to comply with terms of the study

Pediatric Hydrocephalus Inclusion Criteria

- Between ages 7 and 15 years of age;

- Implanted traditional or adjustable hydrocephalus shunt implant (approved or cleared by FDA for pediatric use).

- Neurologic shunt implantation or surgical (in-hospital) adjustment within the past 12 months;

- Signed assent form document from the child

- Signed permission form from the parent/guardian)

Pediatric Hydrocephalus Exclusion Criteria

- Participation in another clinical investigation that could be jeopardized by participation in the current study; and

- Children with severe cognitive impairments (such as children with head injuries resulting in severe cognitive impairment) may be excluded because they may not be capable of self-reporting procedures.6

- Unable to comply with terms of the study

Spinal Cord Injury Inclusion Criteria

- Between ages 14 and 15 years of age;

- Vocare® Bladder System implant (approved or cleared by FDA for pediatric use).

- Neurologic device implanted within the past 12 months;

- Signed assent form document from the child

- Signed permission form from the parent/guardian); and

Spinal Cord Injury Exclusion Criteria

- Participation in another clinical investigation that could be jeopardized by participation in the current study; and

- Children with severe cognitive impairments (such as children with head injuries resulting in severe cognitive impairment) may be excluded because they may not be capable of self-reporting procedures.

- Unable to comply with terms of the study

Deaf or Hearing Impaired Inclusion Criteria

- Between ages 7 and 15* years of age;

- Implanted cochlear implant (approved or cleared by FDA for pediatric use) with any device adjustment related to device performance or routine care of their current device within the past 12 months;

- Signed assent form document from the child

- Signed permission form from the parent/guardian); and

Deaf or Hearing Impaired Exclusion Criteria

- Participation in another clinical investigation that could be jeopardized by participation in the current study; and

- Children with severe cognitive impairments (such as children with head injuries resulting in severe cognitive impairment) may be excluded because they may not be capable of self-reporting procedures.

- Unable to comply with terms of the study

Study Design

Time Perspective: Prospective


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Carlos Pena, PhD, MS
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A